PHILADELPHIA — (Nov. 8, 2019) — Scientists at The Wistar Institute applied synthetic DNA-based technology to drive in vivo production of broadly neutralizing anti-HIV antibodies in small and large-…
PRINCETON, N.J. — PHILADELPHIA — (Oct. 22, 2019) — The American Cancer Society (ACS), the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded …
PHILADELPHIA — (Oct. 17, 2019) — The Wistar Institute and collaborating institutions have received a major grant from the National Institutes of Health to further research on new melanoma targeted …
PHILADELPHIA — (Oct. 9, 2019) — Scientists at The Wistar Institute described a novel mechanism through which astrocytes, the most abundant supporting cells in the brain, also promote cancer cell gr…
PHILADELPHIA — (Oct. 3, 2019) — A novel anticancer molecule created by researchers at The Wistar Institute showed therapeutic activity in preclinical models of various cancer types. This cell-perme…
PHILADELPHIA — (October 1, 2019) — The National Institutes of Health (NIH) today announced that Zachary T. Schug, Ph.D., assistant professor in the Molecular & Cellular Oncogenesis Program at T…
PHILADELPHIA – September 25, 2019 – The Wistar Institute, a global leader in cancer, immunology and infectious disease research, has selected Integral Molecular, Inc. as the first industry partner …
PHILADELPHIA — (September 24, 2019) — The Wistar Institute was awarded two major grants totaling more than $12 million from the National Institute on Drug Abuse (NIDA), part of the National Institu…
PHILADELPHIA — (Sept. 18, 2019) — Researchers at The Wistar Institute have described the role of mitochondrial fission factor (MFF) in controlling survival of cancer cells, suggesting the protein c…
PHILADELPHIA — (September 12, 2019) — The Wistar Institute has received a grant of approximately $4.6 million from the National Institutes of Health in support of innovative research to tackle anti…
